- Home
- ZNTL vs LSAK Comparison
ZNTL vs LSAK Comparison
Compare ZNTL & LSAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- LSAK
- Stock Information
- Founded
- ZNTL 2014
- LSAK 1997
- Country
- ZNTL United States
- LSAK South Africa
- Employees
- ZNTL N/A
- LSAK N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- LSAK Investment Bankers/Brokers/Service
- Sector
- ZNTL Health Care
- LSAK Finance
- Exchange
- ZNTL Nasdaq
- LSAK Nasdaq
- Market Cap
- ZNTL 238.2M
- LSAK N/A
- IPO Year
- ZNTL 2020
- LSAK N/A
- Fundamental
- Price
- ZNTL $3.12
- LSAK $5.10
- Analyst Decision
- ZNTL Buy
- LSAK
- Analyst Count
- ZNTL 7
- LSAK 0
- Target Price
- ZNTL $10.86
- LSAK N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- LSAK 18.4K
- Earning Date
- ZNTL 11-04-2024
- LSAK 11-06-2024
- Dividend Yield
- ZNTL N/A
- LSAK N/A
- EPS Growth
- ZNTL N/A
- LSAK N/A
- EPS
- ZNTL N/A
- LSAK N/A
- Revenue
- ZNTL $40,560,000.00
- LSAK $564,222,000.00
- Revenue This Year
- ZNTL N/A
- LSAK $6.62
- Revenue Next Year
- ZNTL N/A
- LSAK $7.87
- P/E Ratio
- ZNTL N/A
- LSAK N/A
- Revenue Growth
- ZNTL N/A
- LSAK 6.87
- 52 Week Low
- ZNTL $2.83
- LSAK $3.00
- 52 Week High
- ZNTL $18.24
- LSAK $5.33
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- LSAK 58.96
- Support Level
- ZNTL $2.92
- LSAK $4.99
- Resistance Level
- ZNTL $3.23
- LSAK $5.08
- Average True Range (ATR)
- ZNTL 0.17
- LSAK 0.11
- MACD
- ZNTL 0.00
- LSAK 0.01
- Stochastic Oscillator
- ZNTL 38.33
- LSAK 100.00
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.